Institute of Human Virology,
School of Medicine,
Institute of Human Virology, School of Medicine
My main research interest is in virus-host interactions using animal models, genomic profiling, and basic molecular virology. I focused not only on host responses but also on changes that occur in the viral population in order to describe virus-host coevolution. I identified mutations in the arenavirus nucleocapsid protein (NP) that are likely to impact viral pathogenesis and the induction of protective immunity. During my postdoctoral training, I worked in detecting and characterizing HIV viral factors related with latency in the reservoir cells and in implanting patient-derived ATL cells into NSG mice to study cancer pathogenesis and treatment options. Currently, I am using humanized animal models to study infectious diseases (HIV, HTLV, HBV, HCV, and Dengue), human cancers and graft vs host disease (GvHD). I have also detected and characterized a CD8+ T cell sub-population, in humanized mice, that correlated with HIV protection in human beings.
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.
Journal of virology Jun, 2003 | Pubmed ID: 12767990
The proline-rich homeodomain (PRH/HEX) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus.
Journal of virology Feb, 2005 | Pubmed ID: 15681447
Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells.
The Journal of infectious diseases Jan, 2007 | Pubmed ID: 17152007
Early blood profiles of virus infection in a monkey model for Lassa fever.
Journal of virology Aug, 2007 | Pubmed ID: 17522210
Gene expression in primate liver during viral hemorrhagic fever.
Virology journal Feb, 2009 | Pubmed ID: 19216742
Arenavirus variations due to host-specific adaptation.
Viruses Jan, 2013 | Pubmed ID: 23344562
Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate.
PLoS neglected tropical diseases , 2013 | Pubmed ID: 24069471
Modulation of SIV and HIV DNA vaccine immunity by Fas-FasL signaling.
Viruses Mar, 2015 | Pubmed ID: 25807052
Diagnostics for Lassa Fever: Detecting Host Antibody Responses.
Methods in molecular biology (Clifton, N.J.) , 2018 | Pubmed ID: 28986826
A Primate Model for Viral Hemorrhagic Fever.
Methods in molecular biology (Clifton, N.J.) , 2018 | Pubmed ID: 28986843
Development of a serosurveillance assay for detection of Necoclí virus exposure.
Archives of virology Dec, 2018 | Pubmed ID: 30191374
Improving the Breadth of the Host's Immune Response to Lassa Virus.
Pathogens (Basel, Switzerland) Oct, 2018 | Pubmed ID: 30373278
T-Cell Response to Viral Hemorrhagic Fevers.
Vaccines Jan, 2019 | Pubmed ID: 30678246
HIV Replication in Humanized IL-3/GM-CSF-Transgenic NOG Mice.
Pathogens (Basel, Switzerland) Mar, 2019 | Pubmed ID: 30871027
Seroprevalence of human T-lymphotropic virus HTLV and its associated factors in donors of a blood bank of Medellín-Colombia, 2014-2018.
PloS one , 2019 | Pubmed ID: 31404110
A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge.
Pathogens (Basel, Switzerland) Aug, 2019 | Pubmed ID: 31466243
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有,本公司不涉及任何医疗业务和医疗服务。